Table 1.

Percentage of BrdU-positive cells double-labeled with either the neuronal cell marker NeuN or the glial cell marker GFAP (mean ± SEM)

Time of BrdU injection after the 25th seizure	Treatment	DG		Hilus
Time of BrdU injection after the 25th seizure	Treatment	% BrdU + NeuN	% BrdU + GFAP	% BrdU + NeuN	% BrdU + GFAP
0 hr	Con	93.3 ± 0.4	4.9 ± 0.4	9.1 ± 0.7^*	82.4 ± 2.6
	Exp	93.6 ± 0.6	5.1 ± 0.4	7.7 ± 0.8^*	82.2 ± 1.1
		χ² = 0.615	χ² = 0.043	χ² = 4.209	χ² = 3.069
		p = 0.433	p = 0.835	p = 0.040	p = 0.080
3 d	Con	93.5 ± 0.4	3.6 ± 0.2	10.5 ± 0.6^*	83.2 ± 2.1
	Exp	93.3 ± 0.7	4.2 ± 0.3	7.3 ± 0.9^*	85.5 ± 1.1
		χ² = 0.067	χ² = 2.000	χ² = 14.971	χ² = 2.663
		p = 0.795	p = 0.157	p < 0.001	p = 0.103
6 d	Con	90.1 ± 1.5	8.4 ± 1.5	13.0 ± 3.1	81.0 ± 2.3
	Exp	92.1 ± 0.9	7.2 ± 1.7	10.9 ± 2.7	86.0 ± 2.5
		χ² = 1.031	χ² = 0.085	χ² = 0.268	χ² = 0.866
		p = 0.310	p = 0.770	p = 0.604	p = 0.352

χ² values and p values are reported below the proportions (shown as percentages in the table) for the control group and the flurothyl-treated group being compared. Asterisks denote a significant difference between the control and experimental proportions (p < 0.05). Con, Control; Exp, flurothyl-treated group.